PhRMA Statement on Congressional User Fees Agreement

WASHINGTON, D.C. (September 27, 2022) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement following the announced bipartisan deal on passing the prescription drug and biosimilar user fee agreements:

“Reauthorizing the Prescription Drug and Biosimilar User Fee Acts is a win for patients, biopharmaceutical innovation and regulatory predictability.

“We thank members of Congress for their hard work getting these programs reauthorized for another five years and ensuring the U.S. Food and Drug Administration can conduct its vital work reviewing medicines for patients.”

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $800 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.MAT.org
www.Facebook.com/PhRMA
www.X.com/PhRMA